Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
53 /100
HIGH RISK
Score updated Oct 13, 2026

SYRE — Spyre Therapeutics, Inc. Dilution Risk Tracker

Track SYRE dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track SYRE — Get alerts when the score changes →

As of October 13, 2026, Spyre Therapeutics, Inc. (SYRE) has a DilutionWatch DilutionScore of 53/100, rated HIGH dilution risk. Spyre Therapeutics, Inc. has a market capitalization of $7.57B, 88.17M shares outstanding, 199 institutional holders tracked. Stored dilution-related fields include shelf registration capacity of $500.00M, ATM program capacity of $403.00M.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
80
💰 Cash Runway
40
📊 Float Risk
10
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

⛅
Watch
Minor dilution signals detected
model est. 19%
💰 Capital Raise model 38%
• Active shelf registration ($500M, 7% of market cap)
• Active ATM program with $403M remaining capacity
🔔 Track SYRE — Get forecast alerts →

Market Data

Market Cap$7.57B
Shares Outstanding88.17M
Float80.93M
Cash$200.08M
DebtN/A
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore53/100DilutionWatch score record
Shares Outstanding88.17MVerified float table or market cache
Public Float80.93MVerified float table or market cache
Market Cap$7.57BMarket data cache
Cash Runway16.6 monthsDilutionWatch score inputs
Shelf Capacity$500.00MSEC-derived dilution fields
ATM Capacity$403.00MSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 1, 424B5 2, 8-K 1, SC 13G/A 1, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 17.0% shares (2026Q1 vs prior)
199 institutional holders · 95.93M shares
#1 FMR LLC 11.78M shares
#2 PERCEPTIVE ADVISORS LLC 7.57M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 6.11M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest12.84M
Days to Cover8.9
% of Float15.9%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2026-02-19
xbrl XBRL WARRANT 2026-02-19
SC 13G/A BENEFICIAL OWNERSHIP 2026-08-14
424B5 ATM 2026-04-16
8-K 8K EVENT 2026-04-16
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual SYRE Dilution Snapshot

Spyre Therapeutics, Inc. (SYRE) has a DilutionScore of 53/100, rated High dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

SYRE's DilutionScore is currently 53/100 (High risk), with 1 score change tracked over 89 days. The score deteriorated from 61/100 (High risk).

Period Score Risk Level Duration
Aug 22 – Oct 13, 202653/100HIGH53 days
Jul 16 – Aug 21, 202661/100HIGH36 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

SYRE shares outstanding have increased 10.6% from 78.54M (Mar 2026) to 86.84M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 18, 202686.84M80.93M▼ 0.06%
May 12, 202686.84M80.98M▲ 0.10%
May 10, 202686.84M80.90M▲ 5.74%
May 08, 202686.84M76.51M▲ 10.57%
May 04, 202686.26M69.20M▲ 0.02%
Apr 26, 202686.26M69.18M▼ 5.38%
Apr 20, 202686.26M73.12M▲ 13.55%
Apr 07, 202678.54M64.39M▲ 0.02%
Mar 05, 202678.54M64.38M▲ 0.02%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track SYRE Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment SYRE files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking SYRE — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for SYRE
SYRE FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.